Drugs / anti-BCMA/FcRL5 CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06759181 | Dec 2024 → Dec 2027 expected | plasma cell myeloma | Xuzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-BCMA/FcRL5 CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06759181 ↗ |